SLDB
Price
$6.86
Change
-$0.12 (-1.72%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
780.6M
40 days until earnings call
Intraday BUY SELL Signals
XENE
Price
$37.99
Change
-$0.94 (-2.41%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
3.56B
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SLDB vs XENE

SLDB vs XENE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SLDB vs. XENE commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLDB is a Hold and XENE is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
SLDB vs XENE: Fundamental Ratings
SLDB
XENE
OUTLOOK RATING
1..100
8661
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6489
P/E GROWTH RATING
1..100
35
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for XENE (78). This means that SLDB’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for SLDB (100). This means that XENE’s stock grew somewhat faster than SLDB’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as SLDB (98). This means that XENE’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's Price Growth Rating (64) in the Biotechnology industry is in the same range as XENE (89). This means that SLDB’s stock grew similarly to XENE’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as XENE (5). This means that SLDB’s stock grew similarly to XENE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLDBXENE
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 16 days ago
69%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 5 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
71%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (SLDB: $6.98 vs. XENE: $38.93)
Brand notoriety: SLDB and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLDB: 143% vs. XENE: 261%
Market capitalization -- SLDB: $780.6M vs. XENE: $3.56B
SLDB [@Biotechnology] is valued at $780.6M. XENE’s [@Biotechnology] market capitalization is $3.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLDB’s FA Score shows that 2 FA rating(s) are green while XENE’s FA Score has 1 green FA rating(s).

  • SLDB’s FA Score: 2 green, 3 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than XENE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLDB’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 4 bullish TA indicator(s).

  • SLDB’s TA Score: 5 bullish, 5 bearish.
  • XENE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both SLDB and XENE are a good buy in the short-term.

Price Growth

SLDB (@Biotechnology) experienced а -6.68% price change this week, while XENE (@Biotechnology) price change was +2.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

SLDB is expected to report earnings on Nov 11, 2026.

XENE is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
SLDB
Daily Signal:
Gain/Loss:
XENE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UMAY38.810.04
+0.09%
Innovator U.S. Equity Ultra Buffer ETF - May (UMAY)
CLIX56.20N/A
N/A
ProShares Long Online/Short Stores ETF (CLIX)
NVDG18.84N/A
N/A
Leverage Shares 2X Long Nvda Daily ETF
SCYB25.06-0.18
-0.71%
Schwab High Yield Bond ETF (SCYB)
ICOP52.54-0.68
-1.28%
iShares Copper and Metals Mining ETF (ICOP)

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-3.46%
EDIT - SLDB
56%
Loosely correlated
-1.95%
RCKT - SLDB
53%
Loosely correlated
-1.52%
FDMT - SLDB
53%
Loosely correlated
-3.28%
CRBU - SLDB
52%
Loosely correlated
-3.94%
BEAM - SLDB
51%
Loosely correlated
-0.25%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with RLMD. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then RLMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+4.68%
RLMD - XENE
55%
Loosely correlated
-2.92%
MLTX - XENE
44%
Loosely correlated
-1.97%
DNTH - XENE
44%
Loosely correlated
+0.31%
REPL - XENE
42%
Loosely correlated
+1.59%
SLDB - XENE
40%
Loosely correlated
-3.46%
More